查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1344460

出血性疾病市場：依疾病類型、治療類型、通路2023-2032 年全球機會分析與產業預測

Bleeding Disorders Market By Disease Type, By Treatment Type, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 458 Pages | 商品交期: 2-3個工作天內

價格

2022 年出血性疾病市場價值為 138 億美元，預計 2023 年至 2032 年複合年增長率為 6.6%，到 □□2032 年達到 260 億美元。

出血性疾病是一種以無法正常形成血栓為特徵的疾病。 血塊對於受傷或外傷後止血至關重要。 出血性疾病即使是輕微傷害也會導致出血過多，有時會導致內出血。

出血性疾病市場-IMG1

出血性疾病是一組因血液中特定凝血因子缺乏或功能障礙而導致異常出血的疾病。 通常，當一個人受傷或割傷時，身體會形成血塊來止血。 然而，在患有出血性疾病的患者中，此過程受損或缺失，可能導致異常或過量出血。 血友病是最常見的出血性疾病，主要影響男性，並可能導致嚴重的、危及生命的出血事件。 馮維勒布蘭德病也是一種常見的出血性疾病，影響男性和女性，並可能導致受傷或手術後長時間出血。

推動出血性疾病市場成長的關鍵因素是：出血性疾病治療的快速進步，受血友病 A、血友病 B 和其他出血性疾病影響的患者數量不斷增加，例如， 例如，根據美國疾病管制與預防中心 (CDC) 的數據，2022 年美國有 33,000 名男性患有出血性疾病。

此外，政府在血友病管理方面的積極舉措、提高出血性疾病治療意識的計劃以及越來越多的抗血友病藥物開發臨床試驗正在推動出血性疾病市場的成長。 此外，目標族群的增加、診斷率的提高以及血友病預防性治療的普及正在推動市場成長。

然而，血友病治療的高成本以及與血漿衍生產品相關的嚴重副作用預計將限制出血性疾病市場的成長。 相反，快速增長的醫療保健支出、新興國家對更好的血友病治療方案的醫療需求未得到滿足，預計將為未來全球市場擴張創造巨大機會。

目錄

第一章簡介

第 2 章執行摘要

第三章市場概述

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資機會
  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭強度
  • 市場動態
    • 促進因素
      • 血友病患病率不斷上升
      • 血友病治療的技術進步
      • 政府對血友病管理採取積極主動的方法
    • 抑制因素
      • 出血性疾病的治療費用不斷上漲
    • 機會
      • 提高發展中國家對出血性疾病的認知
  • 新冠肺炎 (COVID-19) 市場影響分析

第 4 章出血性疾病市場：依疾病類型劃分

  • 摘要
  • 甲型血友病
  • B型血友病
  • 血管性血友病
  • 其他

第 5 章出血性疾病市場：依治療類型

  • 摘要
  • 因子替代療法
  • 藥物治療

第 6 章出血性疾病市場：依分銷管道劃分

  • 摘要
  • 醫院藥房
  • 藥局和零售藥局
  • 網路藥局

第七章出血性疾病市場：依地區

  • 摘要
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 澳大利亞
    • 印度
    • 韓國
    • 其他亞太地區
  • 拉丁美洲/中東/非洲
    • 巴西
    • 沙烏地阿拉伯
    • 南非
    • 其他領域

第八章競爭態勢

  • 簡介
  • 關鍵成功策略
  • 10家主要公司的產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 2022 年主要公司的定位

第九章公司簡介

  • Pfizer Inc.
  • Novo Nordisk A/S
  • Bayer AG
  • Octapharma AG
  • Sanofi
  • Medexus Pharma, Inc.
  • Grifols, S.A.
  • F. Hoffmann-La Roche Ltd.
  • CSL Limited
  • Takeda Pharmaceutical Company Limited
Product Code: A02466

According to a new report published by Allied Market Research, titled, "Bleeding Disorders Market," The bleeding disorders market was valued at $13.8 billion in 2022, and is estimated to reach $26 billion by 2032, growing at a CAGR of 6.6% from 2023 to 2032. A bleeding disorder is a medical condition characterized by inability of a person to form blood clots properly. Blood clots are essential in stopping bleeding after an injury or trauma. Bleeding disorders may lead to excessive bleeding, even with minor injuries, and may also cause internal bleeding in some cases.

Bleeding Disorders Market - IMG1

Bleeding disorders are a group of conditions characterized by abnormal bleeding due to the deficiency or dysfunction of certain clotting factors in the blood. Normally, when a person experiences an injury or cut, the body forms a clot to stop bleeding. However, in a person with a bleeding disorder, this process is impaired or absent, which may lead to abnormal or excessive bleeding. Hemophilia is the most well-known and common bleeding disorder, which affects mostly males and may result in serious and life-threatening bleeding episodes. Von Willebrand disease is another common bleeding disorder that affects both males and females and may lead to prolonged bleeding after injury or surgery.

Major factors that drive the growth of the bleeding disorders market include rapid advancements in treatment of bleeding disorders; increase in number of patients suffering from hemophilia A, hemophilia B, and other bleeding disorders. For instance, according to the Centers for Disease Control and Prevention (CDC) 2022, 33,000 males in the U.S. live with the bleeding disorder.

Furthermore, favorable government initiatives for hemophilia management, increase in number of awareness programs regarding bleeding disorder treatment and rise in number of clinical trials for the development of antihemophilic drugs boost the growth of bleeding disorders market. In addition, the increase in target population, increase in diagnosis rate, and surge in the use of prophylactic treatment for hemophilia propel the market growth.

However, the high cost of hemophilia treatment, and serious adverse effects associated with plasma derived products are expected to restrict the growth of bleeding disorders market. On the contrary, surge in healthcare expenditure, and unmet medical demands to get better treatment options for hemophilia in developing countries are expected to create immense opportunities for the expansion of the global market in the future.

The bleeding disorders market is segmented on the basis of disease type, treatment type, distribution channel and region. On the basis of disease type, the market is classified into hemophilia A, hemophilia B, Von Willebrand disease and others. On the basis of treatment type, the market is classified into factor replacement therapy, and drug therapy (desmopressin, antifibrinolytics, fibrin sealant). The factor replacement therapy segment is further bifurcated into plasma-derived coagulation factor concentrates, and recombinant coagulation factor concentrates. On the basis of distribution channel, the bleeding disorders market is segmented into hospital pharmacies, drugs stores and retail pharmacies, and online pharmacies. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).

Major players profiled in the report are Bayer AG, CSL Ltd. (CSL Behring), F. Hoffmann-La Roche AG, Grifols, S.A., Medexus Pharma, Inc., Novo Nordisk A/S, Octapharma AG, Pfizer Inc., SANOFI CORPORATION, and Takeda Pharmaceutical Company Limited. The major players in the market have adopted investment, partnership and product approvals as key developmental strategies to improve the product portfolio of the bleeding disorders market.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the bleeding disorders market analysis from 2022 to 2032 to identify the prevailing bleeding disorders market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the bleeding disorders market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global bleeding disorders market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Disease Type

  • Hemophilia A
  • Hemophilia B
  • Von Willebrand Disease
  • Others

By Treatment Type

  • Factor Replacement Therapy
    • Type
    • Recombinant coagulation factor concentrates
    • Plasma derived coagulation factor concentrates
  • Drug Therapy

By Distribution Channel

  • Hospital Pharmacies
  • Drug stores and retail pharmacies
  • Online pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Medexus Pharma, Inc.
    • Bayer AG
    • Novo Nordisk A/S
    • Grifols, S.A.
    • Octapharma AG
    • Takeda Pharmaceutical Company Limited
    • CSL Limited
    • Pfizer Inc.
    • Sanofi
    • F. Hoffmann-La Roche Ltd.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in prevalence of hemophilia
      • 3.4.1.2. Technological advancements in treatment of hemophilia
      • 3.4.1.3. Favorable government initiatives for hemophilia management
    • 3.4.2. Restraints
      • 3.4.2.1. High cost of bleeding disorders treatments
    • 3.4.3. Opportunities
      • 3.4.3.1. Rise in awareness about bleeding disorders in developing countries
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: BLEEDING DISORDERS MARKET, BY DISEASE TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Hemophilia A
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Hemophilia B
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Von Willebrand Disease
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Others
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country

CHAPTER 5: BLEEDING DISORDERS MARKET, BY TREATMENT TYPE

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Factor Replacement Therapy
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
    • 5.2.4. Factor Replacement Therapy Bleeding Disorders Market by Type
  • 5.3. Drug Therapy
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Drug stores and retail pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Online pharmacies
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: BLEEDING DISORDERS MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Disease Type
    • 7.2.3. Market size and forecast, by Treatment Type
    • 7.2.4. Market size and forecast, by Distribution Channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Disease Type
      • 7.2.5.1.3. Market size and forecast, by Treatment Type
      • 7.2.5.1.4. Market size and forecast, by Distribution Channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Disease Type
      • 7.2.5.2.3. Market size and forecast, by Treatment Type
      • 7.2.5.2.4. Market size and forecast, by Distribution Channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Disease Type
      • 7.2.5.3.3. Market size and forecast, by Treatment Type
      • 7.2.5.3.4. Market size and forecast, by Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Disease Type
    • 7.3.3. Market size and forecast, by Treatment Type
    • 7.3.4. Market size and forecast, by Distribution Channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Disease Type
      • 7.3.5.1.3. Market size and forecast, by Treatment Type
      • 7.3.5.1.4. Market size and forecast, by Distribution Channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Disease Type
      • 7.3.5.2.3. Market size and forecast, by Treatment Type
      • 7.3.5.2.4. Market size and forecast, by Distribution Channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Disease Type
      • 7.3.5.3.3. Market size and forecast, by Treatment Type
      • 7.3.5.3.4. Market size and forecast, by Distribution Channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Disease Type
      • 7.3.5.4.3. Market size and forecast, by Treatment Type
      • 7.3.5.4.4. Market size and forecast, by Distribution Channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Disease Type
      • 7.3.5.5.3. Market size and forecast, by Treatment Type
      • 7.3.5.5.4. Market size and forecast, by Distribution Channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Disease Type
      • 7.3.5.6.3. Market size and forecast, by Treatment Type
      • 7.3.5.6.4. Market size and forecast, by Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Disease Type
    • 7.4.3. Market size and forecast, by Treatment Type
    • 7.4.4. Market size and forecast, by Distribution Channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Disease Type
      • 7.4.5.1.3. Market size and forecast, by Treatment Type
      • 7.4.5.1.4. Market size and forecast, by Distribution Channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Disease Type
      • 7.4.5.2.3. Market size and forecast, by Treatment Type
      • 7.4.5.2.4. Market size and forecast, by Distribution Channel
      • 7.4.5.3. Australia
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Disease Type
      • 7.4.5.3.3. Market size and forecast, by Treatment Type
      • 7.4.5.3.4. Market size and forecast, by Distribution Channel
      • 7.4.5.4. India
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Disease Type
      • 7.4.5.4.3. Market size and forecast, by Treatment Type
      • 7.4.5.4.4. Market size and forecast, by Distribution Channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Disease Type
      • 7.4.5.5.3. Market size and forecast, by Treatment Type
      • 7.4.5.5.4. Market size and forecast, by Distribution Channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Disease Type
      • 7.4.5.6.3. Market size and forecast, by Treatment Type
      • 7.4.5.6.4. Market size and forecast, by Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Disease Type
    • 7.5.3. Market size and forecast, by Treatment Type
    • 7.5.4. Market size and forecast, by Distribution Channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Disease Type
      • 7.5.5.1.3. Market size and forecast, by Treatment Type
      • 7.5.5.1.4. Market size and forecast, by Distribution Channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Disease Type
      • 7.5.5.2.3. Market size and forecast, by Treatment Type
      • 7.5.5.2.4. Market size and forecast, by Distribution Channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Disease Type
      • 7.5.5.3.3. Market size and forecast, by Treatment Type
      • 7.5.5.3.4. Market size and forecast, by Distribution Channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Disease Type
      • 7.5.5.4.3. Market size and forecast, by Treatment Type
      • 7.5.5.4.4. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Pfizer Inc.
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. Novo Nordisk A/S
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. Bayer AG
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
  • 9.4. Octapharma AG
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
    • 9.4.7. Key strategic moves and developments
  • 9.5. Sanofi
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
    • 9.5.7. Key strategic moves and developments
  • 9.6. Medexus Pharma, Inc.
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
    • 9.6.7. Key strategic moves and developments
  • 9.7. Grifols, S.A.
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
    • 9.7.7. Key strategic moves and developments
  • 9.8. F. Hoffmann-La Roche Ltd.
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
    • 9.8.7. Key strategic moves and developments
  • 9.9. CSL Limited
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
    • 9.9.7. Key strategic moves and developments
  • 9.10. Takeda Pharmaceutical Company Limited
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance
    • 9.10.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 02. BLEEDING DISORDERS MARKET FOR HEMOPHILIA A, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. BLEEDING DISORDERS MARKET FOR HEMOPHILIA B, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. BLEEDING DISORDERS MARKET FOR VON WILLEBRAND DISEASE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. BLEEDING DISORDERS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. GLOBAL BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 07. BLEEDING DISORDERS MARKET FOR FACTOR REPLACEMENT THERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. GLOBAL FACTOR REPLACEMENT THERAPY BLEEDING DISORDERS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 09. BLEEDING DISORDERS MARKET FOR DRUG THERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 11. BLEEDING DISORDERS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. BLEEDING DISORDERS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. BLEEDING DISORDERS MARKET FOR ONLINE PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. BLEEDING DISORDERS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA BLEEDING DISORDERS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 19. U.S. BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 20. U.S. BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 21. U.S. BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 22. CANADA BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 23. CANADA BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 24. CANADA BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 26. MEXICO BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 27. MEXICO BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 31. EUROPE BLEEDING DISORDERS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 32. GERMANY BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 33. GERMANY BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 34. GERMANY BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 35. FRANCE BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 36. FRANCE BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 37. FRANCE BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 38. UK BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 39. UK BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 40. UK BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 41. ITALY BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 42. ITALY BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 43. ITALY BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 44. SPAIN BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 45. SPAIN BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 46. SPAIN BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 47. REST OF EUROPE BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 48. REST OF EUROPE BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 49. REST OF EUROPE BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 50. ASIA-PACIFIC BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 52. ASIA-PACIFIC BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 53. ASIA-PACIFIC BLEEDING DISORDERS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 54. JAPAN BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 55. JAPAN BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 56. JAPAN BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 57. CHINA BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 58. CHINA BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 59. CHINA BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 60. AUSTRALIA BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 61. AUSTRALIA BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 62. AUSTRALIA BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 63. INDIA BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 64. INDIA BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 65. INDIA BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH KOREA BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH KOREA BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 68. SOUTH KOREA BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 71. REST OF ASIA-PACIFIC BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 72. LAMEA BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 73. LAMEA BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 74. LAMEA BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 75. LAMEA BLEEDING DISORDERS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 76. BRAZIL BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 77. BRAZIL BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 78. BRAZIL BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 79. SAUDI ARABIA BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 80. SAUDI ARABIA BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 81. SAUDI ARABIA BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 82. SOUTH AFRICA BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 83. SOUTH AFRICA BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 84. SOUTH AFRICA BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 85. REST OF LAMEA BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 86. REST OF LAMEA BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 87. REST OF LAMEA BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 88. PFIZER INC.: KEY EXECUTIVES
  • TABLE 89. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 90. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 91. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 92. PFIZER INC.: KEY STRATERGIES
  • TABLE 93. NOVO NORDISK A/S: KEY EXECUTIVES
  • TABLE 94. NOVO NORDISK A/S: COMPANY SNAPSHOT
  • TABLE 95. NOVO NORDISK A/S: PRODUCT SEGMENTS
  • TABLE 96. NOVO NORDISK A/S: PRODUCT PORTFOLIO
  • TABLE 97. NOVO NORDISK A/S: KEY STRATERGIES
  • TABLE 98. BAYER AG: KEY EXECUTIVES
  • TABLE 99. BAYER AG: COMPANY SNAPSHOT
  • TABLE 100. BAYER AG: PRODUCT SEGMENTS
  • TABLE 101. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 102. OCTAPHARMA AG: KEY EXECUTIVES
  • TABLE 103. OCTAPHARMA AG: COMPANY SNAPSHOT
  • TABLE 104. OCTAPHARMA AG: PRODUCT SEGMENTS
  • TABLE 105. OCTAPHARMA AG: PRODUCT PORTFOLIO
  • TABLE 106. OCTAPHARMA AG: KEY STRATERGIES
  • TABLE 107. SANOFI: KEY EXECUTIVES
  • TABLE 108. SANOFI: COMPANY SNAPSHOT
  • TABLE 109. SANOFI: PRODUCT SEGMENTS
  • TABLE 110. SANOFI: PRODUCT PORTFOLIO
  • TABLE 111. SANOFI: KEY STRATERGIES
  • TABLE 112. MEDEXUS PHARMA, INC.: KEY EXECUTIVES
  • TABLE 113. MEDEXUS PHARMA, INC.: COMPANY SNAPSHOT
  • TABLE 114. MEDEXUS PHARMA, INC.: PRODUCT SEGMENTS
  • TABLE 115. MEDEXUS PHARMA, INC.: PRODUCT PORTFOLIO
  • TABLE 116. MEDEXUS PHARMA, INC.: KEY STRATERGIES
  • TABLE 117. GRIFOLS, S.A.: KEY EXECUTIVES
  • TABLE 118. GRIFOLS, S.A.: COMPANY SNAPSHOT
  • TABLE 119. GRIFOLS, S.A.: PRODUCT SEGMENTS
  • TABLE 120. GRIFOLS, S.A.: PRODUCT PORTFOLIO
  • TABLE 121. GRIFOLS, S.A.: KEY STRATERGIES
  • TABLE 122. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 123. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 124. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
  • TABLE 125. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 126. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
  • TABLE 127. CSL LIMITED: KEY EXECUTIVES
  • TABLE 128. CSL LIMITED: COMPANY SNAPSHOT
  • TABLE 129. CSL LIMITED: PRODUCT SEGMENTS
  • TABLE 130. CSL LIMITED: PRODUCT PORTFOLIO
  • TABLE 131. CSL LIMITED: KEY STRATERGIES
  • TABLE 132. TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY EXECUTIVES
  • TABLE 133. TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT
  • TABLE 134. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT SEGMENTS
  • TABLE 135. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT PORTFOLIO
  • TABLE 136. TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. BLEEDING DISORDERS MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF BLEEDING DISORDERS MARKET, 2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN BLEEDING DISORDERS MARKET (2023-2032)
  • FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. LOW BARGAINING POWER OF BUYERS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. LOW THREAT OF NEW ENTRANTS
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALBLEEDING DISORDERS MARKET
  • FIGURE 10. BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF BLEEDING DISORDERS MARKET FOR HEMOPHILIA A, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF BLEEDING DISORDERS MARKET FOR HEMOPHILIA B, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF BLEEDING DISORDERS MARKET FOR VON WILLEBRAND DISEASE, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF BLEEDING DISORDERS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF BLEEDING DISORDERS MARKET FOR FACTOR REPLACEMENT THERAPY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF BLEEDING DISORDERS MARKET FOR DRUG THERAPY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF BLEEDING DISORDERS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF BLEEDING DISORDERS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF BLEEDING DISORDERS MARKET FOR ONLINE PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. BLEEDING DISORDERS MARKET BY REGION, 2022
  • FIGURE 23. U.S. BLEEDING DISORDERS MARKET, 2022-2032 ($MILLION)
  • FIGURE 24. CANADA BLEEDING DISORDERS MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. MEXICO BLEEDING DISORDERS MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. GERMANY BLEEDING DISORDERS MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. FRANCE BLEEDING DISORDERS MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. UK BLEEDING DISORDERS MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. ITALY BLEEDING DISORDERS MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. SPAIN BLEEDING DISORDERS MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. REST OF EUROPE BLEEDING DISORDERS MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. JAPAN BLEEDING DISORDERS MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. CHINA BLEEDING DISORDERS MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. AUSTRALIA BLEEDING DISORDERS MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. INDIA BLEEDING DISORDERS MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. SOUTH KOREA BLEEDING DISORDERS MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. REST OF ASIA-PACIFIC BLEEDING DISORDERS MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. BRAZIL BLEEDING DISORDERS MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. SAUDI ARABIA BLEEDING DISORDERS MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. SOUTH AFRICA BLEEDING DISORDERS MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. REST OF LAMEA BLEEDING DISORDERS MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 45. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 46. COMPETITIVE DASHBOARD
  • FIGURE 47. COMPETITIVE HEATMAP: BLEEDING DISORDERS MARKET
  • FIGURE 48. TOP PLAYER POSITIONING, 2022
  • FIGURE 49. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 50. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 51. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 52. NOVO NORDISK A/S: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 53. NOVO NORDISK A/S: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 54. NOVO NORDISK A/S: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 55. BAYER AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 56. BAYER AG: RESEARCH & DEVELOPMENT EXPENDITURE, 2020-2022 ($MILLION)
  • FIGURE 57. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 58. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 59. OCTAPHARMA AG: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 60. SANOFI S.A.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 61. SANOFI S.A.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 62. SANOFI S.A.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 63. MEDEXUS PHARMA, INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 64. MEDEXUS PHARMA, INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 65. GRIFOLS, S.A.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 66. GRIFOLS, S.A.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 67. GRIFOLS, S.A.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 68. F. HOFFMANN-LA ROCHE LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 69. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 70. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 71. CSL LIMITED: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 72. CSL LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 73. CSL LIMITED: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 74. TAKEDA PHARMACEUTICAL COMPANY LIMITED: NET REVENUE, 2019-2021 ($MILLION)